PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions

Ll, Xia; Liu, Yuanyong; Wang, Ying

doi:10.1634/theoncologist.2019-io-s1-s05

Cited by 266 publications

(200 citation statements)

References 125 publications

Supporting

Mentioning

195

Contrasting

Unclassified

Order By: Relevance

“…Traditional treatments for lung cancer have some insurmountable barriers. For example, molecular targeting drugs may not be effective when genomic testing reveals no targetable alteration, such as epidermal growth factor receptor (EGFR) mutations, anaplastic lymphoma kinase (ALK) or ROS1 translocation/re-arrangements (15). As traditional methods have been shown as ineffective against certain cancer types, the focus has shifted to immune cells, and immunotherapy for lung cancer is attracting increasing attention.…”

Section: Overview Of Immunotherapy In Non-small Cell Lung Cancermentioning

confidence: 99%

Biomarkers of immunotherapy in non‑small cell lung cancer (Review)

Wang

et al. 2020

Oncol Lett

View full text Add to dashboard Cite

Immunotherapy has markedly improved the survival rate of patients with non-small cell lung cancer (NSCLC) and has introduced a new era in lung cancer treatment. However, not all patients with lung cancer benefit from checkpoint blockade, and some suffer from notable immunotoxicities. Thus, it is crucial to identify potential biomarkers suitable for screening the population that may benefit from immunotherapy. Based on the current clinical trials, the aim of the present study was to review the biomarkers for immune checkpoint inhibition, as well as other effective, invalid and hyperprogression markers that may have the potential to better predict responders to immunotherapy among patients with NSCLC. All these biomarkers may be incorporated into the predictive utility of bio-score systems and decision-making algorithms, to better guide the application of immunotherapy in the clinical setting. Contents 1. Introduction 2. Overview of immunotherapy in non-small cell lung cancer 3. Predictors of immunotherapy 4. Conclusions and future perspectives

show abstract

Section: Overview Of Immunotherapy In Non-small Cell Lung Cancermentioning

confidence: 99%

Biomarkers of immunotherapy in non‑small cell lung cancer (Review)

Wang

et al. 2020

Oncol Lett

View full text Add to dashboard Cite

show abstract

“…Recently, FSTL1 neutralizing antibodies were developed and found to display excellent e cacy in vitro [52]. Also, CTLA4, PD-1, and programmed death ligand-1 (PD-L1) inhibitors have shown promising results in lung cancer, yet the response was unclear in advancedstage GC [53,54]. The combined use of FSTL1 neutralizing antibodies with anti-CTLA-4 or anti-PD-1/PD-L1 inhibitors may produce additive or synergistic effects, thus creating a new treatment option.…”

Section: Discussionmentioning

confidence: 99%

Follistatin-like 1 (FSTL1) is a Prognostic Biomarker and Correlated with Immune Cell Infiltration in Gastric Cancer

Huang

Yao

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: Follistatin-like 1 (FSTL1) plays a central role in the progression of tumor and tumor immunity. However, the effect of FSTL1 on the prognosis and immune infiltration of gastric cancer (GC) remains to be elucidated.Method: The expression of FSTL1 data was analyzed in Oncomine and TIMER databases. Analyses of clinical parameters and survival data were conducted by Kaplan-Meier plotter and immunohistochemistry. Western blot assay and real‐time quantitative PCR (RT-qPCR) was using to analyzed protein and mRNA expression, respectively. The correlations between FSTL1 and cancer immune infiltrates was analyzed by Tumor Immune Estimation Resource (TIME), Gene Expression Profiling Interactive Analysis (GEPIA) and LinkedOmics database.Results: The expression of FSTL1 was significantly higher in GC tissues than in normal tissues, and bioinformatic analysis and Immunohistochemistry (IHC) indicated that high FSTL1 expression significantly correlated with poor prognosis in GC. Moreover, FSTL1 was predicted as an independent prognostic factor in GC patients. Bioinformatics analysis results suggested that FSTL1 mainly involved in tumor progression and tumor immunity. And significant correlations were found between FSTL1 expression and immune cell infiltration in GC.Conclusion: The study effectively revealed useful information about FSTL1 expression, prognostic values, potential functional networks and impact of tumor immune infiltration in GC. In summary, FSTL1 can be used as a biomarker for prognosis and evaluating immune cell infiltration in GC.

show abstract

“…ICIs, particularly PD-1/PD-L1 inhibitors, are effective in treating melanoma, [ 29 ] renal cell carcinoma, [ 30 ] and colorectal cancer. [ 31 ] Research evidence shows that PD-1/PD-L1 blockades have improved overall survival (OS) than docetaxel for NSCLC [ 32 ] . The mechanism of PD-1 and PD-L1 inhibitors involves mainly restarting the T cell-mediated tumor cell death process; at the same time, interferes with the normal immune system.…”

Section: Discussionmentioning

confidence: 99%

Adverse cardiac events in the treatment of non-small cell lung cancer with programmed death-1and programmed death-ligand 1 inhibitors

Li¹,

Han²,

Feng

et al. 2020

Medicine

View full text Add to dashboard Cite

Background: Programmed death-1 (PD-1) and programmed death ligand-1 (PD-L1) inhibitors are immune therapies that have shown great promise in the treatment of multiple cancers. However, immune-related adverse events of PD-1 and PD-L1 inhibitors may limit their use in non-small cell lung cancer (NSCLC). Given the rising number of clinical trials in recent years, it is essential to perform a meta-analysis to provide assess the cardiotoxicity of PD-1/ PD-L1 inhibitors in NSCLC therapy. Method and analysis: The ClinicalTrials.gov, Embase, PubMed, and Cochrane Central Register of Controlled Trials repositories will be searched from their inception to December 2019. The bibliography of the searching process will be imported into Endnote X9 software. Two reviewers independently will screen the literature, extract data, and conduct the risk of bias for every added study. The data analysis will be analyzed using Stata15.0 software. Specific adverse cardiac events will be identified, with particular attention on atrial fibrillation, cardiac arrest, cardiac failure, and pericarditis. This review will be performed as per the Preferred Reporting Item for Systematic Review and meta-analysis statement recommendations. Ethics and dissemination: This study will provide support for the cardiotoxicity linked to the treatment of NSCLC using PD-1/PD-L1 inhibitors. The data in the meta-analysis will be retrieved from completed and published clinical trials; therefore, ethical review and patient informed consent will not be required. PROSPERO number: CRD42020156397.

show abstract

PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions

Cited by 266 publications

References 125 publications

Biomarkers of immunotherapy in non‑small cell lung cancer (Review)

Biomarkers of immunotherapy in non‑small cell lung cancer (Review)

Follistatin-like 1 (FSTL1) is a Prognostic Biomarker and Correlated with Immune Cell Infiltration in Gastric Cancer

Adverse cardiac events in the treatment of non-small cell lung cancer with programmed death-1and programmed death-ligand 1 inhibitors

Contact Info

Product

Resources

About